LG Uplus, Kakao Mobility EV Charging Joint Venture Approved by the FTC 
LVMH succession planning: keeping it in the family when you’re the world’s richest man 
OpenAI and Worldcoin Eye Strategic Partnership Amid Regulatory Gaze 
Samsung's Lee Jae-Yong Forges Strategic AI Chip Production Alliance With ZEISS 
Xochitl Gomez Becomes the New Face of Adidas Sportswear 
Liverpool FC Expands into South Korea with First Retail Partnership 
McDonald's Korea Launches 'Mom's Bed' Campaign Highlighting Caregiver Hardships 
KT Innovates Media, Content Business Through AI 
Court Documents Unveil $1 Billion Annual Revenue of Shell's Oil Trading Business in US 
Paramount Ousts CEO Bob Bakish Amid Skydance Merger Talks 
China Beat South Korea in OLED Panel Shipments for Small Gadgets 
Billionaire Moves to Take L’Occitane Private in a $7 Billion Deal 
McDonald's Q1 Earnings Preview: Sales Growth Challenges Ahead 
Deutsche Bank Considers Settlement in Postbank Takeover Litigation 
Tesla Clears Regulatory Hurdles for FSD Launch in China with Baidu's Help 
Four myths about vertical farming debunked by an expert 
Star Entertainment’ David Foster Quits Just Weeks After Appointment 
NEWARK, Calif., Sept. 07, 2016 -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will participate in a fireside chat at the 2016 Morgan Stanley Global Healthcare Conference scheduled for 2:15 pm ET (11:15 am PT) on Monday, September 12, 2016 in New York, New York.
The fireside chat will be webcast live and may be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the event will be archived for 30 days on the company's website.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.
Investor Contact: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 [email protected]
